|
|
Post by ryster505 on May 9, 2024 9:32:37 GMT -5
Peds approval more than year away. Same with mnkd 101 Revenue won’t go up much until then. I don’t believe this is accurate. TDPI revenues should more than double over the next 18-24 months Thank god it’s his 28th, company could have been extinct after his 6th or 8th. |
|
|
|
Post by Clement on May 9, 2024 9:38:29 GMT -5
For the most recent two quarters, MNKD revenues have increased by an average of $7.5M each quarter.
If MNKD continues to increase revenues by $7.5M per quarter, the total for FY2024 will be $309M. That would be more than 54% increase yoy.
|
|
|
|
Post by Clement on May 9, 2024 9:43:42 GMT -5
Note to analysts: XYZ PDQ
|
|
|
|
Post by casualinvestor on May 9, 2024 9:59:32 GMT -5
We may not get this kind of gains every quarter. From Steve Binder answering a question: PPQ = Package Performance Qualification...had to look that one up. However, I think seasonality (historically, Tyvaso sales overall seem to lag Q4 and Q1, then upswing Q2 - see mnkd.proboards.com/post/264448/thread ) and manufacturing improvements will overcome that gap for Q2. |
|
|
|
Post by jkendra on May 9, 2024 10:05:54 GMT -5
MannKind (Biopharmaceutical company, Nasdaq - Ticker MNKD), not to be confused with a retail stock, is trending toward $300M+ in revenues being priced out at 3x earnings. For comparison, biopharmaceutical company Liquidia (LQDA), is being priced out at 200X earnings.  |
|
|
|
Post by mymann on May 9, 2024 10:13:29 GMT -5
You would think the Q1 ER was bad the way sp is behaving.
|
|
|
|
Post by porkini on May 9, 2024 10:17:18 GMT -5
You would think the Q1 ER was bad the way sp is behaving. Easy there, I bought a small handful of shares yesterday morning before the ER, so it is only natural the SP goes down a bit.  |
|
|
|
Post by mango on May 9, 2024 10:55:33 GMT -5
🥭 Run rate of over $250M in revenue for 2024
🥭 Over the past eight quarters, revenue has surged by over 250%
🥭 Record Tyvaso DPI revenue of ~$48M due to strong sales by UTHR and record production in Q1
🥭 Clofazimine received Fast Track Designation
🥭 Clofazimine will have 12 years of exclusivity
🥭 Afrezza Pediatrics approval in 2025
🥭 Nintedanib Phase 1 next month
🥭 Paid off the mid-cap senior secured debt
🥭 Extinguished the convertible debt
🥭 Grew total revenues 63% year over year, another exceptional quarter for revenue growth, and achieved eighth consecutive quarter of revenue growth
|
|
|
|
Post by wyattdog on May 9, 2024 11:09:52 GMT -5
how are you guys thinking about the path forward for MNKD-201? And have you considered potentially working with a partner there just considering how much interest there is in that market? Michael Castagna:And we feel that means if all works out, we should have a clear winner that can help a lot of people and deal with the No. 1 Achilles' heel of the market leader out there. And so if you think about a $3.9 billion drug that's almost $100 million a week out the door in revenue, would I much rather have that for our shareholders versus a partner? I don't think in these diseases, you need a ton of infrastructure that we haven't already built. Meaning specialty support services, pharmacy distribution, wholesalers, patient trainings, and things like that, we have all that.
|
|
|
|
Post by BD on May 9, 2024 11:37:30 GMT -5
I'm sorry but WTF is going on with the SP? I think this is a good example of what they mean by "priced for perfection". |
|
|
|
Post by cretin11 on May 9, 2024 11:44:42 GMT -5
And what’s your issue with that statement? It was a factual statement but not a good way to open the call IMO. I was simply responding to mizzou's question. |
|
|
|
Post by cretin11 on May 9, 2024 11:47:20 GMT -5
how are you guys thinking about the path forward for MNKD-201? And have you considered potentially working with a partner there just considering how much interest there is in that market? Michael Castagna:And we feel that means if all works out, we should have a clear winner that can help a lot of people and deal with the No. 1 Achilles' heel of the market leader out there. And so if you think about a $3.9 billion drug that's almost $100 million a week out the door in revenue, would I much rather have that for our shareholders versus a partner? I don't think in these diseases, you need a ton of infrastructure that we haven't already built. Meaning specialty support services, pharmacy distribution, wholesalers, patient trainings, and things like that, we have all that.Wouldn't share price be responding very differently if the Street had any confidence in the bolded sentence above? We will need a partner, hopefully we get the right one. |
|
|
|
Post by prcgorman2 on May 9, 2024 12:06:56 GMT -5
Looks to me like the Street is still treating MNKD as a speculative high-risk stock but showing more confidence in terms of the floor.
I think MTOI's advice ("Buy all the cheap shares you can.") continues to be good.
|
|
|
|
Post by mango on May 9, 2024 12:10:14 GMT -5
how are you guys thinking about the path forward for MNKD-201? And have you considered potentially working with a partner there just considering how much interest there is in that market? Michael Castagna:And we feel that means if all works out, we should have a clear winner that can help a lot of people and deal with the No. 1 Achilles' heel of the market leader out there. And so if you think about a $3.9 billion drug that's almost $100 million a week out the door in revenue, would I much rather have that for our shareholders versus a partner? I don't think in these diseases, you need a ton of infrastructure that we haven't already built. Meaning specialty support services, pharmacy distribution, wholesalers, patient trainings, and things like that, we have all that.Wouldn't share price be responding very differently if the Street had any confidence in the bolded sentence above? We will need a partner, hopefully we get the right one. Mike seems to disagree with you on needing a partner. As he pointed out, we have the infrastructure already in place to bring a drug to market solo. Why give up a large percentage of the profits to a partner when we are capable of doing it solo? The barriers to entry are very low in this particular market with very little competition. Our DPI version has the potential to be the preferred drug over Ofev, in terms of safety/side effect profile, efficacy and patient/physician preference. |
|
|
|
Post by prcgorman2 on May 9, 2024 12:37:02 GMT -5
I'm sorry but WTF is going on with the SP? The same as has always been the case. There is literally no demand or interest in the stock from those that matter in the market, i.e, top tier brokerage houses and institutions. Short interest = still high Institutional investors = <50% Low level brokerage firms only cover. The street truly does not like this company nor does it equate the royalty income as growth. The best way to describe this stock as it being a utility stock without issuing a dividend. Corrections:
Institutional investment continues to be >50%. (But not by much.)
Coverage [market cap or valuation]:
Cantor Fitzgerald [$487M]
H.C. Wainwright & Co. [N/A]
Oppenheimer & Co. [$444M]
Royal Bank of Canada [$144B]
SVB Leerink [$6.2B]
Wedbush [$4.14B]
It may be unfair to characterize the brokerage firms that cover MNKD to be "low level brokerage firms only", and RBC, SVB Leerink, and Wedbush especially.
|
|
